DKP101

DKP101 is a small molecule drug candidate being developed by Dongkwang as an "improved new drug" (Incrementally Modified Drug or IMD) for urological indications. In the South Korean regulatory framework, an improved new drug typically refers to a product with a modified formulation, dosage form, or a new combination of existing active pharmaceutical ingredients that offers improved efficacy or safety. While the specific mechanism of action for DKP101 has not been officially disclosed by Dongkwang, it is categorized within their pipeline as a urological treatment. As of 2020, the program was reported to be in the preclinical or early development stage.